Psychiatric Outcomes of Unruptured Intracranial Aneurysms (POUIA)

Last updated: November 16, 2025
Sponsor: Montefiore Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Depression

Anxiety Disorders

Panic Disorders

Treatment

Clipping

Endovascular embolization

Endovascular embolization

Clinical Study ID

NCT06123325
2023-15285
  • Ages 18-75
  • All Genders

Study Summary

The impact of cerebrovascular procedures on patients experiencing anxiety and depression is not well studied despite the high prevalence of these mental health disorders. Unruptured Intracranial aneurysms (UIAs) have a prevalence of approximately 3% and an annual risk of 1-2% in the general population. Despite the high risk of fatality following aneurysm rupture with a rate of 40-50%, the overall aneurysm growth and rupture risks are rare (less than 3% per aneurysm per year) and many patients can be observed with serial follow-up imaging over years. Nevertheless, due to the gravity of the bad consequences of aneurysm rupture, simply informing many patients of UIA diagnosis has been found to result in worse outcomes of health-related quality of life. This study aims to investigate the impact of awareness of untreated UIA on the patients' mental health utilizing the Hospital Anxiety and Depression Scale (HADS) tool.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Unruptured intracranial aneurysms (UIA)

  • mRS scores between 0-1

  • Observation Group: All patients with UIAs that are eligible for conservativemanagement

  1. Specific locations that are not good candidates for interventional treatment,such as cavernous internal carotid artery and very distally located aneurysms

  2. Aneurysm size (largest dimension) is less than 4 mm

  • Treatment Group: All patients with UIAs that are decided to be treated either withendovascular or microsurgical treatments due to several reasons, such as aneurysmsize above 4 mm, patient's decision

Exclusion

Exclusion Criteria:

  • Prior history of Subarachnoid Hemorrhage (SAH)

  • Prior history of intracranial aneurysm

  • Severe comorbidities that impact the mental health of the patients, such severepsychiatric disease, and chronic end stage diseases

  • Traumatic, mycotic, dissecting, or fusiform aneurysms

  • Patients with communication barriers (does not include foreign language),developmental disability, or psychiatric illness that prevent understanding of thequestions required to complete assessments

  • Patients with any physical disabilities or handicaps

Study Design

Total Participants: 120
Treatment Group(s): 4
Primary Treatment: Clipping
Phase:
Study Start date:
December 01, 2023
Estimated Completion Date:
September 30, 2027

Study Description

This is a controlled, non-randomized, prospective cohort study with parallel arms of treatment arm with microsurgical and endovascular treatment and comparison control arm with conservative management/observation of UIA. The goal of this study is to investigate the impact of the awareness of an untreated UIA on the psychiatric and mental status of the patients enrolled in the control arm compared to patients with a treated UIA. All patients presenting to the outpatient clinic upon the initiation of the trial and for 2 years ahead with UIA diagnosed on any of the angiographic imaging modalities including Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA), and Digital Subtraction Angiogram (DSA) will be included.

Connect with a study center

  • Montefiore Medical Center

    Bronx, New York 10467
    United States

    Site Not Available

  • Montefiore Medical Center

    The Bronx 5110266, New York 5128638 10467
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.